Posted on 11/12/2023 8:53:41 PM PST by ConservativeMind
New research shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty liver disease, especially in women and men who are 50 years old and younger.
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease marked by chronic joint inflammation leading to joint damage and loss of function. It can also affect tissues and organs outside the joints, including the eyes, heart, and lungs. Although not a classic complication of RA, nonalcoholic fatty liver disease (NAFLD or MAFLD), is prevalent among RA patients, affecting about 35% of men and 22% of women.
The researchers drew on population-based claims data from the National Health Insurance Research Database in Taiwan from 2000 to 2020. The study included more than 21,000 patients, with a mean standard deviation age of 51.9, and the ratio of women to men was 3 to 2.
A time-varying, multivariable Cox regression model was used to estimate the adjusted hazard ratios with 95% confidence interval for an association between HCQ and NAFLD, after adjusting for potential confounders. Subgroup analyses looked at patients based on sex and age (men and women younger and older than 50).
The study's results show that 399 (1.86%) patients developed NAFLD after more than eight years. The study also suggests taking HCQ was associated with a significantly lower risk of NAFLD, especially in women younger than 50.
Chen says this association may be due to the effect of HCQ on adiponectin, an adipokine inversely linked to insulin resistance, inflammation and NAFLD.
"The mechanism of decreasing the risk of NAFLD by HCQ may be its [ability] to increase adiponectin levels," Chen says. "Estrogen has been reported to inhibit adiponectin production and estrogens are inversely associated with adiponectin levels. Therefore, the reduced NAFLD risk with HCQ may be more prominent in premenopausal women."
(Excerpt) Read more at medicalxpress.com ...
So, after folks started using Ivermectin, doctors started seeing that it was having beneficial effects on cancer patients.
Enter a video floating around of a doctor explaining that it would appear that ‘parasitic clusters’ are being misdiagnosed as ‘tumors’. Hence, the anti-parasitic effects of Ivermectin are working to rid folks of these ‘clusters’(tumors).
Of course, Big Pharma would fight to the death, any attempt at research into this hypothesis as it would mean no more chemotherapy drugs for many.
The hidden benefits of ivermectin should be studied. If it turns out to be the Swiss army knife of benefits, the research will generate profit for those who finance it. The word “wealth” has a nice ring to it.
Please explain how that profit occurs. Would this be the underpants gnome business model?
Yeah, but you have to inject Drano into your body before that hydro stuff works. I’m pretty sure CDC gave us the heads up on this stuff three years ago.
This “study” is extremely weak, at best. It is a retroactive look at records in a database. Actual details of patient care are lacking.
Because of the nature of statistics, an analysis which finds that A correlates with B is actually a spurious result. “Spurious” means it isn’t real.
Physicians who are not trained in research theory and methodology love to do these kinds of studies, as it does not involve actually designing a rigorous controlled study. All they have to do is comb through databases and hand over the numbers to the statistician to crunch. If the statistician finds a correlation between any two variables in the numbers, the physician has something to publish. And these studies are just about worthless.
Only a randomized clinical trial (RCT) can demonstrate a real cause-and-effect relationship. In the drug development world, that clinical trial typically does not happen until the candidate drug has been shown to have therapeutic effect in animals, although someone might be able to ethically justify doing a trial of HCQ in humans. The Medical Xpress article even says this.
Given that the development of NAFLD only occurs in 1.86% of RA patients, the RCT would have to enroll a large number of participants.
There are other issues with this retrospective crunching of numbers from a registry, as well. For example, only 399 people out of 41,791 were recorded as having developed NAFLD. Obesity, NSAID use, and prednisolone use were all associated with development of NAFLD. These are probably more valid associations than the association of HCQ with decrease of NAFLD. This is because 399 NAFLD patients were being compared against a huge background of 41,392 patients who did not develop NAFLD. But the converse, trying to compare 41,392 patients who did not develop NAFLD against a background of 399 who did is problematic.
My VA doc is gonna flip.
They already studied it and were so impressed they gave the inventor the Nobel Peace Prize in Medicine. Not veterinarian medicine. HUMAN Medicine.
Covid came along they tossed it all under the bus in hopes of even bigger and more wealth.
this would be especially interesting if hcq could reduce fatty liver disease in people who did not have rheumatoid arthritus. Most— but not all— people with pot bellies have some kind of fatty liver disease.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.